Literature DB >> 22872300

EuroQol 5D quality of life in Menière's disorder can be explained with symptoms and disabilities.

Hilla Levo1, Dafydd Stephens, Dennis Poe, Erna Kentala, Jyrki Rasku, Ilmari Pyykkő.   

Abstract

The purpose of this study was to determine the factors explaining changes in the generic quality of life among patients with Menière's disorder (MD) and to evaluate the EuroQol 5D (EQ-5D) quality-of-life measures. A questionnaire focusing on symptoms and disabilities caused by MD was collected from 726 individuals. General health-related quality of life (EQ-5D) was evaluated using the time trade-off (TTO) and visual-analogue scale (VAS). Personal traits were measured with the sense of coherence. The TTO-VAS score difference was modeled with activity limitations, participation restrictions, attitudes, and symptoms. For TTO as the outcome measure, one symptom-based, three attitude-based, one activity limitation, and one participation restriction item explained 43% of the variability. For VAS, six attitude-based, one symptom-based, three activity limitations, and one participation restriction item explained 43% of the variability of the data. The correlation between TTO and VAS (r=0.515, P<0.001) explained only 27% of the variance. The difference between TTO and VAS was reflected in attitudes towards the illness. The model explained 10% of the variability in the VAS and TTO difference. There was a disease duration effect in the TTO-VAS difference. In conclusion, a symptom-based model combined with disabilities provided a good description of general quality of life in MD. The TTO-based and VAS-based evaluation explained somewhat different aspects of MD. The difference between TTO and VAS could be described as an attitude toward the ailment. Evaluation of disabilities and the difference in TTO and VAS can be used to guide the rehabilitation to promote attitude change.

Entities:  

Mesh:

Year:  2012        PMID: 22872300     DOI: 10.1097/MRR.0b013e3283531f95

Source DB:  PubMed          Journal:  Int J Rehabil Res        ISSN: 0342-5282            Impact factor:   1.479


  8 in total

1.  Dizziness in Europe: from licensed fitness to drive to licence without fitness to drive.

Authors:  Doreen Huppert; Dominik Straumann; Mans Magnusson; Ilmari Pyykkö; Thomas Brandt
Journal:  J Neurol       Date:  2018-03-13       Impact factor: 4.849

2.  The Reliability and Validity of "Dokuz Eylül University Meniere's Disease Disability Scale".

Authors:  Başak Mutlu; Günay Kırkım; Serpil Mungan Durankaya; Selhan Gürkan; Tahsin Oğuz Başokçu; Enis Alpin Güneri
Journal:  J Int Adv Otol       Date:  2018-08       Impact factor: 1.017

3.  Identification of two novel mutations in FAM136A and DTNA genes in autosomal-dominant familial Meniere's disease.

Authors:  Teresa Requena; Sonia Cabrera; Carmen Martín-Sierra; Steven D Price; Anna Lysakowski; José A Lopez-Escamez
Journal:  Hum Mol Genet       Date:  2014-10-09       Impact factor: 6.150

Review 4.  What is Menière's disease? A contemporary re-evaluation of endolymphatic hydrops.

Authors:  R Gürkov; I Pyykö; J Zou; E Kentala
Journal:  J Neurol       Date:  2016-04-15       Impact factor: 4.849

5.  Disease Profiling for Computerized Peer Support of Ménière's Disease.

Authors:  Jyrki Rasku; Ilmari Pyykkö; Hilla Levo; Erna Kentala; Vinaya Manchaiah
Journal:  JMIR Rehabil Assist Technol       Date:  2015-09-03

6.  Does the Self-training in Ménière's Disease Fit the Disease Characteristics and Help Alleviate the Balance Problems?

Authors:  Ilmari Pyykkö; Nora Pyykkö; Jing Zou; Vinaya Manchaiah
Journal:  J Int Adv Otol       Date:  2022-01       Impact factor: 1.316

7.  Impact evaluation and association with EuroQol 5D health-related utility values in Ménière's disease.

Authors:  Ilmari Pyykkő; Vinaya Manchaiah; Hilla Levo; Erna Kentala
Journal:  Springerplus       Date:  2015-11-24

8.  Patient-reported benefits from patient organization magazines and Internet-based peer support in Ménière's disease.

Authors:  Vinaya Manchaiah; Ilmari Pyykkö; Jing Zou; Hilla Levo; Erna Kentala
Journal:  Patient Prefer Adherence       Date:  2017-10-26       Impact factor: 2.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.